Fluorescence guidance can enable a colorectal surgeon to assess cancer tissues visually and with more specificity in real-time during surgery, by using near-infrared (NIR) light from an administered fluorophore in conjunction with artificial intelligence (AI) methods, according to research lead by Professor Ronan Cahill, professor of surgery at University College Dublin (UCD) and the Mater Misericordiae University Hospital, Ireland. The findings, ‘Artificial intelligence indocyanine green (ICG) perfusion for colorectal cancer intra-operative tissue classification’, were published in the British Journal of Surgery,
"Surgery has the substantial role to play in the therapy of over two-thirds of all cancers and key surgical decisions are traditionally made by human visual judgements, which assume a static biological FOV (Field of View) during the time frame of the observation (which in surgery is moments),” explained Cahill. "The process for uptake and release of an external substance, such as drugs and contrast agents, are unique in cancerous tissues. As such, we envisaged that an approach combining biophysics-inspired modelling and AI could analyse intraoperative changes in NIR intensities over time in varied tissue, enabling clinically useful lesion classification with high specificity. To translate this knowledge for the first time into an intraoperative surgical decision support tool, a computer vision-AI real time tissue-tracking and categorizing protype has been developed. As the prototype relies only on the NIR fluorescence data stream, it is usable with commercially available imaging systems."
In this study, supported by the Disruptive Technologies and Innovation Fund 2018, videos from 24 patient (11 with cancer) surgeries were studied. Numerous ROIs (Regions of Interest) from each area of abnormality were selected for analysis from each video. NIR intensities were extracted by tracking the ROIs within each video, focusing on the initial wash-in period. The data set used for analysis included 435 ROI profiles each with 12 perfusion-characterising features with balanced outcomes. At patient level, the system correctly diagnosed 19 of 20 cancers (95%.)
"Targeted agents for cancer imaging currently under trial adhere rigidly to conventional paradigms of fluorescence guided surgery mechanisms, and in the main are administered systemically before surgery, with the operation scheduled for when maximum stable contrast between the tumour and other tissues exist,” added Professor Donal O'Shea, Department of Chemistry at RCSI University of Medicine and Health Sciences. “However, this timing is often unpredictable, it can take some days and false positives can occur. Clinical usefulness is further limited by dosing practicalities, scheduling challenges and patient-to-patient and cancer-to-cancer differences. This work instead indicates a novel pathway and process for immediate, perfect realisation of agent information during surgery which would greatly improve efficiency and effectiveness of cancer care."